New targeted agents in gastroenteropancreatic neuroendocrine tumors

Targeted Oncology

Volumn 7, Issue 2, 2012, Pages 99-106

  Benavent, Marta ^a   De Miguel, Maria Jose ^a   Garcia Carbonero, Rocio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Everolimus; Gastroenteropancreatic; Neuroendocrine; Sunitinib; Targeted agents; Therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; CYCLIN DEPENDENT KINASE 2; CYCLOPHOSPHAMIDE; ENDOSTATIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; OXALIPLATIN; PAZOPANIB; PEGINTERFERON ALPHA2B; PERTUZUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TUBERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; DIARRHEA; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; SKIN TOXICITY; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84865772391     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0218-9     Document Type: Review

References (29)

1. Yao JC, Hassan M, Phan A et al (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
2. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21:1794-1803
3. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61-72
4. Oberg K (2009) Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors. Curr Opin Endocrinol Diabetes Obes Feb 16(1):72-78
5. García-Carbonero R, Salazar R, Sevilla I, Isla D (2011) SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol 13:545-551
6. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027 (Pubitemid 46202320)
7. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (21):4368-4380 (Pubitemid 35266299)
8. Zhang J, Jia Z, Li Q et al (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109(8):1478-1486 (Pubitemid 46595681)
9. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23(5):939-952 (Pubitemid 46202314)
10. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)
11. Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410
12. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
13. Yao JC, Phan A, Hoff PM et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 26:1316-1323
14. Yao JC, Phan A, Fogleman D (2010) Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 28(15):4002
15. Hobday TJ, Rubin J, Holen K et al (2007) MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol (Meeting Abstracts) 25(18-suppl):4504
16. Castellano D, Capdevila J, Salazar R et al (2010) Neuroendocrine tumors. Ann Oncol 21(suppl 8):850, Abstract
17. Phan AT, Yao JC, Fogelman KR et al (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendo-crine carcinoma (LGNEC). J Clin Oncol 28:15s (suppl; abstr 4001)
18. Capdevila J, Teule DE, Castellano D et al (2011) PAZONET: a phase II trial of pazopanib in patients with metastatic neuroendo-crine tumors (NETs) who may have previously received antiangio-genic or mTOR treatment. J Clin Oncol 29 (suppl; abstr TPS171)
19. García-Carbonero R, Castellano D, Lacasta A et al (2012) Randomized phase II double-blind study of axitinib versus placebo in combination with octeotride LAR in patients with progressive advanced well-differentiated (WD) neuroendocrine carcinomas (NECs) of non-pancreatic origin (AXI-IIG-02). J Clin Oncol 30 (suppl; abstr TPS)
20. Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2):128-135 (Pubitemid 34155123)
21. Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1 and mTOR pathway genes are frequently altered in pancreatic neuro-endocrine tumors. Science 331(6021):1199-1203
22. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27 (13):2278-2287
23. Oberstein PE, Saif MW (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6:41-51
24. Moreno A, Akcakanat A, Munsell MF et al (2008) Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257-266 (Pubitemid 351449744)
25. Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuro-endocrine carcinomas. Br J Cancer 95:1148-1154 (Pubitemid 44660065)
26. Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311-4318
27. Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroen-docrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69-76
28. Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RA-DIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005-2012
29. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523